Feature | August 23, 2013

Peripheral Artery Disease-Related Amputations Are Costly For Hospitals, Economy and Patients

The Sage Group research looks at these costs of amputation

August 23, 2013 — At the opening session of the third annual Amputation Prevention Symposium (AMP) in Chicago, Mary L. Yost, president of The Sage Group, delivered a lecture titled “Amputation Is It Really Cost-Effective.”

 “Amputation for critical limb ischemia (CLI) is not cost-effective,” said Yost. “The most recent cost-effectiveness analysis demonstrated that amputation was less cost-effective than either surgical or endovascular revascularization.

“Despite being less cost-effective than revascularization, 65,000-70,000 major amputations (above-the-knee and below-the-knee) are performed annually for CLI. The annual cost exceeds $10 billion. Medicare and Medicaid pay almost 80 percent of the bill.

“Published research, as well as our own analysis, demonstrates that amputation actually costs the hospital more than either surgical bypass or endovascular revascularization. Although initial procedure costs are similar, total amputation costs including the costs of in-hospital mortality, morbidity and revision procedures are higher than those of either bypass or endovascular.”

With regard to patient costs associated with amputation, Yost said, “These costs are significant and include lost wages of the patient and family caregiver, copayments and deductibles and modifications for disabled living such as handrails, wheelchair ramps and wheelchair accessible transportation.”

“The costs are not just monetary. Major amputation is frequently a tragedy for patients and their families. In-hospital morbidity and mortality is high. Above-knee and below-knee amputations are two of the top five surgical procedures with the highest perioperative mortality,” she explained.

Commenting on post-discharge patient outcomes Yost said, “For those surviving the procedure, outcomes and quality of life after amputation are dismal. Most amputees undergo a lengthy healing process, 35 percent experience depression, and almost all suffer from chronic pain as well as perceive themselves to be severely physically impaired. Sixty to 80 percent cannot walk; contralateral amputation occurs in 36-50 percent and at two years mortality is 30-50 percent.”

Peripheral artery disease (PAD), also known as peripheral vascular disease (PVD) is characterized by a reduction of blood flow to the lower limbs due to atherosclerosis. In CLI, the most severe and deadly form of PAD, blood flow is so inadequate that rest pain, ulcerations or gangrene occur. Within five years, approximately 70 percent of CLI patients die. This mortality rate exceeds that of coronary artery disease, breast cancer and colorectal cancer.

For more information: www.thesagegroup.us

 

Related Content

News | Genetic Testing| July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Abbott, Absorb bioresorbable stent, dissolving, UAB, University of Alabama at Birmingham, first in state
News | Stents Bioresorbable| July 26, 2016
On July 20, Massoud Leesar, M.D., of University of Alabama at Birmingham Hospital implanted a patient with Absorb, the...
CMS, Overall Hospital Quality Star Rating, national distribution, quailty of care
News | Business| July 26, 2016
July 25, 2016 — The Centers for Medicare and Medicaid Services (CMS) announced that it expects to launch its new Over
Stryker Sustainability Solutions, Angiodynamics Soft Vu Omni Flush Angiographic Catheters, recall
News | Angiographic Catheter| July 25, 2016
Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush...
Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS

The Abbott Absorb stent gained FDA clearance in July 2016. It has metallic markers at each end so it can be visualized for proper positioning under angiographic X-ray imaging. 

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Overlay Init